Conferences - Results from #300

Viewing 301-320 of 11728 articles

ASCO 2024: Debunking the Frailty-Sarcopenia-ADT Axis in Metastatic Prostate Cancer with Multicomponent Exercise: The FIERCE Trial

ASCO 2024: A Phase II Trial of Enzalutamide with 5-Alpha Reductase Inhibitors as an ADT–Sparing Approach for Older Men with CSPC

ASCO 2024: Bone Resorptive Agents and Their Appropriate Use and Timing

ASCO 2024: Impact of Alterations in Tumor Suppressor Genes on Survival Outcomes in Patients with De Novo mCSPC Cancer Receiving ADT with ARPI or Docetaxel

ASCO 2024: Discussion: The Needle in the Haystack: Finding Biomarkers in Kidney Cancer

ASCO 2024: Discussion: Tailoring Treatment and Navigating Patient Preferences

ASCO 2024: ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Spaces

ASCO 2024: ARV-766, a PROTAC Androgen Receptor Degrader, in mCRPC: Initial Results of a Phase 1/2 Study

ASCO 2024: Prognostic PSMA-PET PROMISE Nomograms for Patients with Prostate Cancer

ASCO 2024: A Phase 1 Study of JNJ-69086420 (JNJ-6420), an Actinium-225 (225Ac)-Labeled Antibody Targeting Human Kallikrein 2, for mCRPC

ASCO 2024: Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer

ASCO 2024: Blood-Based Markers of Differential Efficacy of Bipolar Androgen Therapy and Enzalutamide in the Randomized TRANSFORMER Trial

ASCO 2024: DeLLpro-300: Phase 1b Study of Tarlatamab in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer

ASCO 2024: Nivolumab and Ipilimumab for Metastatic Prostate Cancer with an Immunogenic Signature: The NEPTUNES Multi-Centre Two-Cohort, Biomarker-Selected Phase 2 Trial

ASCO 2024: Oncogenic Alteration Rates, Race, and Prostate Cancer Specific Mortality in Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor next Generation Sequencing

ASCO 2024: Biomarker Analyses in Patients with Advanced Renal Cell Carcinoma from the Phase 3 CLEAR Trial

ASCO 2024: HERCULES (LACOG 0218): A Phase II Trial of Pembrolizumab plus Platinum-Based Chemotherapy as First-Line Systemic Therapy in Advanced Penile Cancer

ASCO 2024: A Randomized Phase II Study of ADT + Abiraterone Versus ADT + Abiraterone + Docetaxel in Patients with Low-Volume Metastatic Hormone-Sensitive Prostate Cancer

ASCO 2024: Characterization of Complete Responders to Nivolumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone and Patients with Lymph Node–only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial

ASCO 2024: Biomarker Analysis of the Phase 3 KEYNOTE-426 Study of Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

11
12
13
14
15
16
17
18
19
20